President and CEO of AMAG Pharmaceuticals Inc. (AMAG, Financial) Brian Jg Pereira sells 5,000 shares of AMAG on 08/05/2009 at an average price of $45 a share.
AMAG Pharmaceuticals Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol the company\'s key product candidate is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.Combidex? the company\'s other product under development is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005 the company received an approvable letter from the FDA with respect to Combidex subject to certain conditions. AMAG Pharmaceuticals Inc. has a market cap of $769.5 million; its shares were traded at around $45.2 with and P/S ratio of 397.1.
Recent Trades of AMAG Pharmaceuticals Inc. by Directors and Officers:
AMAG Pharmaceuticals Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol the company\'s key product candidate is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.Combidex? the company\'s other product under development is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005 the company received an approvable letter from the FDA with respect to Combidex subject to certain conditions. AMAG Pharmaceuticals Inc. has a market cap of $769.5 million; its shares were traded at around $45.2 with and P/S ratio of 397.1.
Recent Trades of AMAG Pharmaceuticals Inc. by Directors and Officers:
- Buy: 10% Owner Capital Partners Gp Llc Adage bought 11,028 shares of AMAG stock on 03/12/2009 at the average price of $25.32; the price of the stock has increased by 78.52% since.
- Buy: 10% Owner Capital Partners Gp Llc Adage bought 84,609 more shares of AMAG stock on 03/11/2009 at the average price of $25.41; the price of the stock has increased by 77.88% since.
- Buy: 10% Owner Capital Partners Gp Llc Adage bought 133,061 more shares of AMAG stock on 03/04/2009 at the average price of $26.64; the price of the stock has increased by 69.67% since.
- Sell: SVP, Commercial Operations Timothy G Healey sold 399 shares of AMAG stock on 08/03/2009 at the average price of $45.48; the price of the stock has decreased by 0.62% since.
